Health Economics›Bladder cancer›Neoadjuvant chemotherapy

Neoadjuvant chemotherapy

Bladder cancer · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	~4.7 mo	~11.5 mo	~2	~R 573 911 PFS proxy · indirect	4
Cisplatin and Gemcitabine (GC) and Pembrolizumab Variant #01	—	R 85 626	21d	~8.3 mo	~17.0 mo	~36	~R 2 992 297 PFS proxy · indirect	2
Atezolizumab monotherapy Variant #01	—	R 31 255	21d	—	~24.3 mo	~2	~R 62 509 PFS proxy · indirect	3
MVAC Variant #02	—	R 5 442	28d	—	89.5 mo	2	R 10 883 PFS proxy	1
Cisplatin and Gemcitabine (GC) Variant #01	—	R 3 933	21d	—	—	6	R 23 595 PFS proxy	1
MCV Variant #01	—	R 3 697	28d	—	44.0 mo	3	R 11 090 PFS proxy	1
MVAC, dose-dense Variant #01	—	R 2 481	14d	—	—	3	R 7 442 PFS proxy	1
No neoadjuvant therapy Partial	—	—	—	—	46.0 mo	—	—	2

8 of 8 regimens shown